Opendata, web and dolomites

pBioStrat-for-PDA SIGNED

Use of PAP as a biomarker and stratifier of pancreatic cancer to improve patient management

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 pBioStrat-for-PDA project word cloud

Explore the words cloud of the pBioStrat-for-PDA project. It provides you a very rough idea of what is the project "pBioStrat-for-PDA" about.

acinar    limiting    candidates    2011    serum    cancer    opened    consists    negative    erc    validation    predict    cellular    titration    figures    criteria    reg3a    trying    microenvironment    biological    panr    outlook    chemotherapy    pap    peri    understand    pbiostrat    resectability    tumors    cells    constitutes    patients    unnecessary    clinicians    morbidity    grant    potent    characterizing    starting    delay    pda    biomarker    poc    clinical    specificity    powerful    took    cohorts    neural    pancreatic    rate    signalling    adenocarcinoma    90    improvements    mortality    2016    start    prognosis    managements       optimization    80    secreted    surgery    tumoral    palliative    context    worst    revealed    discoveries    tool    jak2    survival    nature    interestingly    conceptual    shortening    stromal    demonstrated    consequence    invasion    last    incidence    physiology    with    fundamental    compartment    solid    stratify    stat3    tumor    redirection    progresses    ductal    trials    invasive    neglecting   

Project "pBioStrat-for-PDA" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 150˙000.00

Map

 Project objective

With an overall 3-year survival rate of only ~6% together with an increased incidence pancreatic ductal adenocarcinoma (PDA), which represents 90% of pancreatic cancer, figures as the solid cancer with the worst prognosis. In trying to understand “the” reason for such negative outlook, one has to consider that the fundamental and clinical research conducted during the last 30 years has focused on characterizing and understanding the properties of the PDA cancer cells, neglecting the specific cellular context of those tumors. Indeed PDA consists of 80% of non-tumor cells. In the ERC Starting grant, S-Target-in-PANR, I conducted from 2011 to 2016 we took into account this specificity and analyzed the impact of this stromal compartment on PDA physiology. The discoveries and conceptual progresses obtained throughout the S-Target-in-PANR programme opened new potent improvements of PDA patients’ management. Among them, we revealed that one of the candidates, PAP/REG3A, was secreted by acinar cells from the peri-tumoral microenvironment to enhance peri-neural invasion ability of tumor cells. Interestingly, we demonstrated that PAP/REG3A titration in serum was a potent biomarker in order to stratify PDA and could lead to patients’ management optimization and more specifically to predict resectability. This validation, using robust cohorts and adapted testing, constitutes the main goal of our ERC-PoC pBioStrat-for-PDA. Indeed, it will provide a powerful tool for clinicians in order to better determine the resectability of a tumor by taking into account its biological nature on top of the only clinical criteria used so far. As a consequence the use of a non-invasive PAP/REG3A serum level determination will improve patients’ managements by (1) shortening the delay to start palliative chemotherapy, (2) limiting unnecessary surgery with important mortality/morbidity and (3) improving their redirection to adapted clinical trials, as the one targeting JAK2/STAT3 signalling.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PBIOSTRAT-FOR-PDA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PBIOSTRAT-FOR-PDA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CARBYNE (2020)

New carbon reactivity rules for molecular editing

Read More  

PonD (2019)

Particles-on-Demand for Multiscale Fluid Dynamics

Read More  

ENUF (2019)

Evaluation of Novel Ultra-Fast selective III-V Epitaxy

Read More